Epistaxis During Antiplatelet and Anticoagulant Therapy in Patients with Cardiovascular Disease: Clinical Dilemmas, Guideline Comparison, and a Personalized Management Algorithm

Background and Objective. Epistaxis is a frequent bleeding manifestation in patients receiving antithrombotic therapy, and its management falls between otolaryngology and cardiology guidance. We aimed to translate the evidence into an operational framework for joint decisions. Methods. PubMed/MEDLINE, Scopus, Embase, and the Cochrane Library were searched (January 2015 through August 2026), current ESC, ACC/AHA, EHRA, AAO-HNS, and SFORL guidance were analyzed, and national clinical protocols of different countries were screened; 67 sources were included. Results. Direct oral anticoagulants were consistently associated with fewer clinically relevant epistaxis events than warfarin, and minor epistaxis led to permanent anticoagulant discontinuation more often than minor bleeding at other sites. No guideline defines epistaxis severity, and guidance diverges on protected dual antiplatelet therapy, bleeding-risk assessment, and the sequence of local hemostasis and drug interruption. We propose a three-tier severity classification (minor, clinically relevant non-major, major) informed by ISTH and BARC definitions, a pragmatic thrombotic risk stratification, and an algorithm with agent-specific decisions. Conclusions. In minor and most clinically relevant non-major episodes, antithrombotic therapy can usually be continued while local hemostasis is achieved; interruption, de-escalation, or reversal should be individualized and reserved for uncontrolled or major bleeding. Effective local hemostasis can help avoid unnecessary interruption of antithrombotic therapy, and otolaryngologists should be part of multidisciplinary teams managing such bleeding.

Authors

Institutions

Publication Details

Journal
Diseases
Published
2026-11-12
DOI
https://doi.org/10.3390/diseases14110414
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Epistaxis During Antiplatelet and Anticoagulant Therapy in Patients with Cardiovascular Disease: Clinical Dilemmas, Guideline Comparison, and a Personalized Management Algorithm

ZhZh Toktarova, Farida Rustamova, А.Б. Альмуханова, Assel Issabekova et al.
Diseases
Antiplatelet Therapy and Cardiovascular Diseases
article

Epistaxis During Antiplatelet and Anticoagulant Therapy in Patients with Cardiovascular Disease: Clinical Dilemmas, Guideline Comparison, and a Personalized Management Algorithm

ZhZh Toktarova, Farida Rustamova, А.Б. Альмуханова, Assel Issabekova, Нурбай Жанар Нурбайкызы, Шолпан Болатовна Жангелова, D. A. Kapsultanova, Akhmetzhan Sugraliyev, А.А. Имангалиева, Zhanetta Mukanova, Friba Nurmukhammad, Токбулатова М.О., A. K. Izhanova, Gulzada Nurgaliyeva, Galiya Zhansarina, Rimma Suatbayeva, Kanatbek Mukanov
article en

Abstract

Background and Objective. Epistaxis is a frequent bleeding manifestation in patients receiving antithrombotic therapy, and its management falls between otolaryngology and cardiology guidance. We aimed to translate the evidence into an operational framework for joint decisions. Methods. PubMed/MEDLINE, Scopus, Embase, and the Cochrane Library were searched (January 2015 through August 2026), current ESC, ACC/AHA, EHRA, AAO-HNS, and SFORL guidance were analyzed, and national clinical protocols of different countries were screened; 67 sources were included. Results. Direct oral anticoagulants were consistently associated with fewer clinically relevant epistaxis events than warfarin, and minor epistaxis led to permanent anticoagulant discontinuation more often than minor bleeding at other sites. No guideline defines epistaxis severity, and guidance diverges on protected dual antiplatelet therapy, bleeding-risk assessment, and the sequence of local hemostasis and drug interruption. We propose a three-tier severity classification (minor, clinically relevant non-major, major) informed by ISTH and BARC definitions, a pragmatic thrombotic risk stratification, and an algorithm with agent-specific decisions. Conclusions. In minor and most clinically relevant non-major episodes, antithrombotic therapy can usually be continued while local hemostasis is achieved; interruption, de-escalation, or reversal should be individualized and reserved for uncontrolled or major bleeding. Effective local hemostasis can help avoid unnecessary interruption of antithrombotic therapy, and otolaryngologists should be part of multidisciplinary teams managing such bleeding.

DiseasesVol. 14(11)
Kazakh National Medical University (KZ), Astana Medical University (KZ)
Good health and well-being
Antiplatelet Therapy and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon